Chia‐I Shen

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer

Chia‐I Shen, Chi‐Lu Chiang, Tsu‐Hui Shiao et al. · Scientific Reports · 2022 · 41 citations · Full text

Medicine, Molecular Biology, Oncology +17

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Chia‐I Shen, Heng‐Sheng Chao, Tsu‐Hui Shiao et al. · Scientific Reports · 2021 · 23 citations · Full text

Medicine, Oncology, Chemotherapy +13

Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)

Hsiang‐Yu Lin, Hao-Chuan Liu, Yu-Hsiu Huang et al. · BMJ Open · 2013 · 21 citations · Full text

Life Sciences, Cardiology, Genetics +11

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa

Hsiang‐Yu Lin, Yu-Hsiu Huang, Hsuan-Chieh Liao et al. · Journal of the Chinese Medical Association · 2014 · 20 citations

Life Sciences, Biochemistry, Cardiology +16

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI

Chi‐Lu Chiang, Hsu-Ching Huang, Chia‐I Shen et al. · Targeted Oncology · 2020 · 18 citations

Medicine, Oncology, Molecular Oncology +13